Ubiquitination and proteolysis of cancer-derived Smad4 mutants by SCFSkp2

被引:74
作者
Liang, M
Liang, YY
Wrighton, K
Ungermannova, D
Wang, XP
Brunicardi, FC
Liu, XD
Feng, XH
Lin, X
机构
[1] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
[2] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA
[3] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA
关键词
D O I
10.1128/MCB.24.17.7524-7537.2004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Smad4/DPC4, a common signal transducer in transforming growth factor beta (TGF-beta) signaling, is frequently inactivated in human cancer. Although the ubiquitin-proteasome pathway has been established as one mechanism of inactivating Smad4 in cancer, the specific ubiquitin E3 ligase for ubiquitination-mediated proteolysis of Smad4 cancer mutants remains unclear. In this report, we identified the SCFSkp2 complex as candidate Smad4-interacting proteins in an antibody array-based screen and further elucidated the functions of SCFSkp2 in mediating the metabolic instability of cancer-derived Smad4 mutants. We found that Skp2, the Skp2 F-box component of SCFSkp2, physically interacted with Smad4 at the physiological levels. Several cancer derived unstable mutants exhibited significantly increased binding to Skp2, which led to their increased ubiquitination and accelerated proteolysis. These results suggest an important role for the SCFSkp2 complex in switching cancer mutants of Smad4 to undergo polyubiquitination-dependent degradation.
引用
收藏
页码:7524 / 7537
页数:14
相关论文
共 56 条
  • [1] The proteasome: structure, function, and role in the cell
    Adams, J
    [J]. CANCER TREATMENT REVIEWS, 2003, 29 : 3 - 9
  • [2] Aberrant ubiquitin-mediated proteolysis of cell cycle regulatory proteins and oncogenesis
    Bashir, T
    Pagano, M
    [J]. ADVANCES IN CANCER RESEARCH, VOL 88, 2003, 88 : 101 - 144
  • [3] SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells
    Bhattacharya, S
    Garriga, J
    Calbó, J
    Yong, T
    Haines, DS
    Graña, X
    [J]. ONCOGENE, 2003, 22 (16) : 2443 - 2451
  • [4] Mechanisms of disease:: Role of transforming growth factor β in human disease.
    Blobe, GC
    Schiemann, WP
    Lodish, HF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (18) : 1350 - 1358
  • [5] SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
    Carrano, AC
    Eytan, E
    Hershko, A
    Pagano, M
    [J]. NATURE CELL BIOLOGY, 1999, 1 (04) : 193 - 199
  • [6] Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO
  • [7] 2-Q
  • [8] TGF-β signaling in tumor suppression and cancer progression
    Derynck, R
    Akhurst, RJ
    Balmain, A
    [J]. NATURE GENETICS, 2001, 29 (02) : 117 - 129
  • [9] Smads:: Transcriptional activators of TGF-β responses
    Derynck, R
    Zhang, Y
    Feng, XH
    [J]. CELL, 1998, 95 (06) : 737 - 740
  • [10] The ubiquitin-proteasome pathway of intracellular proteolysis
    Doherty, FJ
    Dawson, S
    Mayer, RJ
    [J]. PROTEASES IN BIOLOGY AND MEDICINE, 2002, 38 : 51 - 63